[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"st-segment-elevation-myocardial-infarction-stemi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:st-segment-elevation-myocardial-infarction-stemi":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,45,69,101,132,158,184,220,245,267,295,320,343,369,394,416,440,467,493,514,547],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100507796","anti-coagulation-on-left-ventricular-thrombus-after-st-segment-elevation-myocardial-infarction-100507796",false,"NCT05892042","Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","ACTonLVT","Inclusion Criteria:\n\nEstablished ST segment elevation myocardial infarction within 7 days Left ventricular thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE.\n\nOngoing treatment with dual anti-platelet therapy according to ESC\u002FAHA guidelines at the time of randomization\n\nExclusion Criteria:\n\nClinically or hemodynamically unstable planed major surgeon such as CABG or Valve replacement within next 12 months Concomitant condition that requires anti- coagulation therapy, such as AF, DVT.\n\nAny contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who is currently pregnant, or breastfeeding serious impaired renal and liver functions life expectancy less than 1 year can not provide consent","ALL","18 Years","80 Years",{"count":21,"type":22},320,"ESTIMATED","INTERVENTIONAL",[25],"NA","Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction",[28,29],"ST-segment Elevation Myocardial Infarction (STEMI)","Left Ventricular Thrombus",[31],"STEMI, LVT, Anticoagulation","RECRUITING","2026-05-27",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2023-05-01",{"date":40,"type":22},"2026-12-01",{"name":42,"class":43},"Jilin University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100575205","phase-4-intracoronary-rhtnk-tpa-versus-tirofiban-in-patients-with-stemi-and-high-thrombus-burden-100575205","NCT06769256","Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden","Effects of Intracoronary Recombinant Human TNK Tissue-type Plasminogen Activator Versus Tirofiban on Myocardial Perfusion and Clinical Prognosis in Patients With ST-segment Elevation Myocardial Infarction and High Thrombus Burden: a Multicenter, Randomized, Controlled, Single-blind, Non-inferior Study","H2-THROMBUS","Inclusion Criteria:\n\n* Age 18-75 years old;\n* STEMI within 12 hours of onset;\n* TIMI flow grade 0-2 or TIMI thrombus grade ≥4 after thrombus aspiration or balloon dilation\n* Radial artery access\n\nExclusion Criteria:\n\n* A functional coronary collateral supply (Rentrop grade≥2) to the infarctrelated artery\n* Known or suspected old myocardial infarction of target vessels\n* Rescue PCI\n* Cardiogenic shock\n* Contraindications to Tirofiban or rhTNK-tPA\n* Severe hepatic and renal insufficiency (alanine aminotransferase ≥5 upper limit of normal; estimated glomerular filtration rate \\\u003C30ml\u002Fmin\u002F1.73m2, or on dialysis)\n* Prolonged (\\> 10 minutes) cardiopulmonary resuscitation\n* Definite mechanical complications (including ventricular septal perforation, or rupture of the Papillary tendon bundle, or rupture of the left ventricular free wall)\n* Severe chronic obstructive pulmonary disease or respiratory failure\n* Severe infection\n* Neurological disorders\n* Malignant tumors or other pathophysiological conditions with an expected survival time of less than 1 year\n* Pregnant or lactating women","75 Years",{"count":55,"type":22},300,[57],"PHASE4","The goal of this clinical trial is to compare the efficacy and safety of intracoronary rhTNK-tPA or Tirofiban in patients with ST-segment elevation myocardial infarction and high thrombus burden. The main questions it aims to answer are:\n\n* Is the efficacy of intracoronary rhTNK-tPA non-inferior to intracoronary Tirofiban for the treatment of ST-segment elevation myocardial infarction in patients wiht high thrombus burden?\n* Does intracoronary rhTNK-tPA increase the incidence of bleeding events?\n\nThis multicenter RCT study plans to enroll 300 patients, who are randomly divided into two groups: intracoronary rhTNK-tPA or Tirofiban by 1:1. The primary efficacy endpoint was post-PCI corrected TIMI frame count (CTFC). Major adverse events (death, recurrent myocardial infarction, ischemic stroke, or hospitalization for heart failure) were observed at 1 year follow-up.",[28],"2026-05-19",{"date":62,"type":36},"2026-05-22",{"date":64,"type":36},"2025-01-01",{"date":66,"type":22},"2027-12-30",{"name":68,"class":43},"Henan Institute of Cardiovascular Epidemiology",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100635362","efficacy-of-thrombus-aspiration-in-patients-with-acute-st-segment-elevation-myocardial-infarction-a-prospective-multicenter-randomized-controlled-single-blind-clinical-trial-100635362","NCT07551700","Efficacy of Thrombus Aspiration in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized, Controlled, Single-Blind Clinical Trial","Efficacy of Thrombus Aspiration in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized, Controlled, Single-Blind Clinical Trial (TRAP-MI)","TRAP-MI","Inclusion Criteria:\n\n* Aged ≥18 years old, diagnosed with acute ST-segment elevation myocardial infarction (STEMI) (chest pain plus ST-segment elevation ≥1mm or new-onset left bundle branch block \\[LBBB\\]) with symptom onset \\\u003C 12 hours.\n* Planned to undergo primary percutaneous coronary intervention (PPCI).\n* High thrombus burden in the target vessel (TIMI thrombus grade ≥3, or visible floating thrombus) confirmed by coronary angiography.\n* Reference diameter of the target vessel ≥2.75mm, with the lesion suitable for the passage of an aspiration catheter.\n* Provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Cardiogenic shock (Killip class IV) or requiring mechanical circulatory support.\n* A history of previous coronary artery bypass grafting (CABG).\n* Concurrent intervention required for non-culprit vessels.\n* Severe bleeding tendency (e.g., INR \\> 2.5, platelet count \\\u003C 50×10⁹\u002FL).\n* Severe renal insufficiency (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 ml\u002Fmin\u002F1.73m²).\n* Expected survival time \\\u003C 1 year (e.g., advanced malignant tumor).",{"count":78,"type":22},6760,[25],"The goal of this clinical trial is to learn if adding standardized manual thrombus aspiration to primary percutaneous coronary intervention (PPCI) works better to improve heart health outcomes and protect long-term heart function in adults with acute ST-segment elevation myocardial infarction (STEMI) and a high blood clot burden in the heart's arteries. The main questions it aims to answer are:\n\n* Does PPCI plus manual thrombus aspiration lower the risk of serious heart problems one year after treatment, compared to PPCI alone?\n* Can manual thrombus aspiration better protect long-term heart function in people with a high blood clot burden? Researchers will compare two groups of participants-one group getting PPCI plus manual thrombus aspiration and one group getting only PPCI-to see if the aspiration treatment leads to fewer serious heart problems, better long-term heart function, and similar safety (including no higher risk of stroke).\n\nParticipants will:\n\n* Have a heart artery scan (coronary angiography) to confirm a high blood clot burden\n* Be randomly assigned to one of the two treatment groups for their PPCI procedure\n* Complete follow-up checks at 30 days, 6 months, and 1 year after treatment, including heart function tests (like echocardiograms)\n* Have heart magnetic resonance (CMR) scans if selected, to measure heart tissue damage and heart function\n* Have their heart health status and any adverse events recorded throughout the study",[28],[83,84,85,86,87,88,89,90],"Acute ST-Segment Elevation Myocardial Infarction","STEMI","Thrombus Aspiration","Primary Percutaneous Coronary Intervention","PPCI","High Thrombus Burden","Randomized Controlled Trial","Multicenter Trial","NOT_YET_RECRUITING","2026-04-20",{"date":94,"type":36},"2026-04-27",{"date":96,"type":22},"2026-04-01",{"date":98,"type":22},"2028-12-31",{"name":100,"class":43},"First Affiliated Hospital Xi'an Jiaotong University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100634216","phase-4-adenosine-pre-medication-in-primary-percutaneous-coronary-intervention-100634216","NCT07536802","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial","AMPACT","Inclusion Criteria:\n\n* All patients with acute STEMI undergoing primary PCI\n* Patients of either sex, ≥18 years of age.\n\nExclusion Criteria:\n\n* STEMI patients with cardiogenic shock at presentation\n* Patients with heart block\n* Allergy to adenosine\n* Patients refuse to give consent for participation",{"count":110,"type":22},1148,[57],"Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow\u002Fno-reflow after primary percutaneous coronary intervention.",[114,115,116,117],"ST-Segment Elevation Myocardial Infarction (STEMI)","No-Reflow Phenomenon","Coronary Slow Flow","Acute Myocardial Infarction",[119,120,114,115,116,121],"Adenonsine","Primary Percutaneous Coronary Intervention (Primary PCI)","Myocardial Reperfusion","2026-04-17",{"date":124,"type":36},"2026-04-22",{"date":126,"type":36},"2025-06-01",{"date":128,"type":22},"2026-12-31",{"name":130,"class":43},"National Institute of Cardiovascular Diseases, Pakistan",2,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100627499","a-privacy-preserving-ocr-llm-system-for-coronary-syndrome-subtyping-from-admission-hpi-multicenter-validation-in-china-and-the-us-100627499","NCT07449429","A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicenter Validation in China and the US","Development and Multicenter Validation of a Privacy-Preserving OCR-LLM Pipeline for Four-Subtype Coronary Syndrome Classification Using Admission HPI Across Heterogeneous EHR Systems","OCR-LLM-CHD","Inclusion Criteria:Hospital encounters with admission HPI documenting sym\n\n2a4afaef-9dc1-47fc-874f-9dffaf7…\n\nevant to coronary syndrome subtyping.\n\nCases with sufficient documentation to assign one of four target subtypes (STEMI, NSTEMI, UA, CCS) by adjudication.\n\n\\-\n\nExclusion Criteria: Unclear subtype or incomplete\u002Funcertain time information preventing gold standard assignment.\n\nNon-CHD primary reason for admission after screening (for MIMIC-IV cohort).\n\n\\-",{"count":141,"type":22},10,"OBSERVATIONAL","This study develops and validates a privacy-preserving OCR-LLM pipeline that converts admission history of present illness (HPI) records into structured coronary syndrome subtypes (STEMI, NSTEMI, unstable angina, and chronic coronary syndrome). The system first extracts text from de-identified HPI images using locally deployed OCR, then applies large language models with a fixed diagnostic prompt to generate subtype classification and evidence. Performance is evaluated in an internal validation cohort and multiple external datasets covering heterogeneous EHR templates, emergency department cases, and an English dataset from MIMIC-IV. A clinician usability study assesses changes in diagnostic accuracy and time with and without tool assistance.",[145,146,28,147],"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))","Acute Coronary Syndromes","Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)","2026-02-27",{"date":150,"type":36},"2026-03-04",{"date":152,"type":22},"2026-02-28",{"date":154,"type":22},"2026-03-08",{"name":156,"class":157},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100327134","systemic-organ-communication-in-stemi-100327134","NCT03539133","Systemic Organ Communication in STEMI","SYSTEMI","Inclusion Criteria:\n\n* Patients suffering from STEMI\n\nExclusion Criteria:\n\n* \\\u003C 18 years",{"count":166,"type":22},1000,"Despite progress in pre-hospital care, ambulance logistics, pharmacotherapy and PPCI techniques, ST-segment elevation myocardial infarction (STEMI) continues to confer a substantial burden of morbidity and mortality.\n\nWithin the STEMI population, there is a spectrum of higher and lower risk patients. The aim of this cohort study is to collect prospectively and systematically clinical research data from STEMI patients. This cohort study is an open-end observational study to identify master switches in myocardial ischemia.",[28],[84,170,171,172,173,174],"infarction","coronary artery disease","comorbidities","diabetes","anemia","2026-01-20",{"date":177,"type":36},"2026-01-22",{"date":179,"type":36},"2017-10-18",{"date":181,"type":22},"2030-06",{"name":183,"class":43},"Heinrich-Heine University, Duesseldorf",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":192,"targetDuration":193,"studyType":142,"phases":4,"briefSummary":194,"conditions":195,"keywords":203,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":44},"100598543","using-cardiac-mri-to-predict-outcomes-in-patients-with-stemi-100598543","NCT07072858","Using Cardiac MRI to Predict Outcomes in Patients With STEMI","Prognostic Value of Cardiac Magnetic Resonance Parameters in Patients With ST-Segment Elevation Myocardial Infarction","CMR-RISK-STEMI","Inclusion Criteria:\n\n* Age between 18 and 80 years\n\nDiagnosed with ST-segment elevation myocardial infarction (STEMI), defined as chest pain with ST-segment elevation on ECG and elevated cardiac troponin levels\n\nUnderwent primary percutaneous coronary intervention (PCI)\n\nAble to undergo cardiac magnetic resonance (CMR) imaging within 7 days post-PCI\n\nProvided written informed consent\n\nExclusion Criteria:\n\n* Contraindications to CMR (e.g., severe claustrophobia, implanted cardiac defibrillators or non-compatible pacemakers)\n\nHistory of revascularization therapy (PCI or CABG) within the previous 6 months\n\nSevere valvular heart disease or known cardiomyopathy\n\nPresence of bundle branch block or fascicular block that interferes with image interpretation\n\nKnown allergy to gadolinium-based contrast agents (for those undergoing contrast-enhanced sequences)\n\nEstimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² (if contrast use is anticipated)\n\nPregnant or breastfeeding women",{"count":166,"type":22},"5 Years","This prospective, multicenter observational study aims to evaluate the prognostic value of a comprehensive set of cardiac magnetic resonance (CMR) imaging parameters in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The study integrates advanced artificial intelligence (AI) techniques to extract and analyze high-dimensional imaging features from multiple CMR sequences-including cine, strain mapping, and functional sequences-going beyond traditional measures such as infarct size or microvascular obstruction.\n\nThe primary objective is to identify novel prognostic markers from routinely acquired CMR images that reflect myocardial structure, function, and mechanical deformation (strain), and to assess their association with long-term clinical outcomes. In addition to standard parameters, the study includes a detailed evaluation of left and right ventricular systolic and diastolic volumes, ejection fractions, and biventricular strain components (including longitudinal, circumferential, and radial strain), as well as left and right atrial volumes, emptying fractions, and reservoir\u002Fconduit\u002Fbooster strain indices.\n\nApproximately 1000 STEMI patients will undergo CMR scanning within one week after PCI. The imaging data will be subjected to AI-based feature extraction and dimensionality reduction algorithms to uncover latent patterns associated with adverse outcomes. Patients will be followed for up to three years for the occurrence of major adverse cardiovascular events (MACE), including cardiovascular death, recurrent myocardial infarction, and heart failure hospitalization.\n\nThe central hypothesis is that comprehensive CMR functional and strain-derived parameters, when analyzed using AI-driven models, offer independent and incremental prognostic value beyond conventional clinical risk factors. This study seeks to establish a data-driven, multimodal imaging framework for personalized risk stratification in STEMI patients, potentially enabling more precise post-infarction management strategies.\n\nNo investigational treatment is involved. All imaging and clinical data are collected as part of routine care and analyzed retrospectively for outcome prediction.",[196,197,198,199,200,201,202],"Myocardial Infarction (MI)","ST Segment Elevation Myocardial Infarction (STEMI)","Magnetic Resonance Imaging (MRI)","Heart Ventricles","Artificial Intelligence (AI)","Prognosis","Ventricular Dysfunction",[204,205,206,207,208,209,210],"ST Segment Elevation Myocardial Infarction","Cardiac Magnetic Resonance Imaging","Cardiac Strain Imaging","Machine Learning","Image Analysis","Survival Analysis","Multimodal Imaging","2025-07-09",{"date":213,"type":36},"2025-07-18",{"date":215,"type":36},"2014-01-01",{"date":217,"type":22},"2025-12-30",{"name":219,"class":43},"Chinese PLA General Hospital",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":241,"leadSponsor":243,"locationsCount":44},"100590421","early-beta-blocker-administration-in-stemi-patients-with-scai-b-status-100590421","NCT06967194","Early Beta Blocker Administration in STEMI Patients With SCAI B Status","Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status","Inclusion Criteria:\n\n* Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.\n* Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and\u002For hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output \\>0.5 mL\u002Fkg\u002Fhour).\n* Age 18 years or older.\n* Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Inability to provide informed consent.\n* Evidence of pulmonary edema.\n* Bradycardia (heart rate \\\u003C60 beats per minute).\n* PR interval \\>240 milliseconds.\n* Second- or third-degree atrioventricular (AV) block.\n* Active asthma.\n* Known hypersensitivity to metoprolol.",{"count":228,"type":22},200,[25],"This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.\n\nWhen patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.\n\nDuring the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.\n\nThe main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.",[197,232],"Cardiogenic Shock Post Myocardial Infarction",[234,235,236],"acute MI","stemi","beta blockers","2025-05-21",{"date":239,"type":36},"2025-05-28",{"date":237,"type":36},{"date":242,"type":22},"2027-06",{"name":244,"class":157},"Tel-Aviv Sourasky Medical Center",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":44},"100589231","coronary-aspiration-catheter-clinical-trial-100589231","NCT06951724","Coronary Aspiration Catheter Clinical Trial","A Prospective, Multicenter, Randomized Controlled, Noninferiority Clinical Trial Evaluating the Efficacy and Safety of an Aspiration Catheter in Patients Undergoing PCI for Acute ST-Segment Elevation Myocardial Infarction (STEMI)","Inclusion Criteria:\n\n\\- General inclusion criteria\n\n1. Age 18-80 years old (inclusive);\n2. Clinical diagnosis of acute ST-segment elevation myocardial infarction (STEMI) within 24 hours of the onset of the disease (where ST-segment elevation is defined as ST-segment elevation of ≥1mm or 0.1mV in 2 or more consecutive leads of the 12-lead ECG);\n3. Voluntary participation and signed written informed consent. Imaging Inclusion Criteria\n4. DSA image showed that the target lesion was in situ coronary artery lesion;\n5. Target vessel TIMI thrombus load classification ≥ grade 3 and TIMI flow classification ≤ grade 1;\n\nExclusion Criteria:\n\n\\- General exclusion criteria\n\n1. previous PCI intervention or coronary artery bypass grafting (CABG) in the target vessel;\n2. Comorbid cardiogenic shock;\n3. severe renal failure or ongoing dialysis;\n4. severe coagulation abnormalities (e.g., hypercoagulability due to blood disorders);\n5. Failure of preoperative thrombolysis requiring remedial PCI;\n6. Serious bleeding events requiring transfusion therapy within 30 days prior to surgery;\n7. Ischemic stroke within 3 months prior to surgery;\n8. Known allergy to anticoagulant and antiplatelet agents or contrast media;\n9. female subjects who are known to be pregnant or lactating;\n10. Participation or planned participation in other clinical studies of drugs or devices;\n11. other conditions that the investigator evaluates to be unsuitable for participation in this trial.\n\n    Imaging exclusion criteria\n12. Prognostic aspiration catheter needs to pass through the original stent mesh to reach the thrombus aspiration site;\n13. severe calcification or tortuosity of the target vessel or extreme angulation that would interfere with the passage of the suction catheter;\n14. the presence of an unprotected left main lesion (more than 50% narrowing of the lumen diameter);\n15. the presence of severe triple coronary artery lesions requiring revascularization.",{"count":253,"type":22},144,[25],"To evaluation of the efficacy and safety of an aspiration catheter in patients undergoing PCI for acute ST-segment elevation myocardial infarction (STEMI).",[28],"2025-04-23",{"date":259,"type":36},"2025-04-30",{"date":261,"type":36},"2025-02-20",{"date":263,"type":22},"2026-06-30",{"name":265,"class":266},"BrosMed Medical Co., Ltd","INDUSTRY",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":276,"conditions":277,"keywords":280,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":44},"100587392","machine-learning-to-boost-the-early-diagnosis-of-acute-cardiovascular-conditions-100587392","NCT06927791","MAchine Learning to Boost the Early Diagnosis of Acute Cardiovascular Conditions","MALBEC","Inclusion Criteria:\n\n• Acute cardiovascular disease (ACVD)\n\nExclusion Criteria\n\n* age \\\u003C 18 years old\n* patients presenting in cardiogenic shock\n* chronic terminal kidney failure requiring dialysis",{"count":275,"type":22},200000,"The research project aims to develop clinical decision support tools integrating established diagnostic variables and machine learning (ML) models for rapid diagnosis of acute life-threatening cardiovascular conditions in emergency department (ED) patients with chest pain or dyspnea with the ultimate goal of Improved diagnostic accuracy, faster patient management, and reduced medical errors.",[278,28,279],"Acute Cardiovascular Disease","NSTEMI - Non-ST Segment Elevation MI",[207,281,282,283,284,285],"Clinical Decision Support Tool","Cardiac Biomarkers","Deep Transfer Learning (DTL)","Artificial Intelligence","Acute cardiovascular conditions","2025-04-07",{"date":288,"type":36},"2025-04-15",{"date":290,"type":36},"2024-04-01",{"date":292,"type":22},"2027-03",{"name":294,"class":43},"University Hospital, Basel, Switzerland",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":316,"leadSponsor":318,"locationsCount":44},"100581227","phase-3-the-investigator-administers-intracoronary-adrenaline-via-the-catheter-in-stemi-patients-during-primary-pci-after-flow-restoration-and-before-stenting-and-studies-its-effect-in-prevention-of-no-reflow-100581227","NCT06847568","The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow","Role of Catheter Administered Intracoronary Epinephrine in Prevention of No-Reflow in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Patients who are 18 years or older\n2. Patients presenting with acute coronary syndrome with ECG criteria diagnostic of STEMI (according to the universal definition of myocardial infarction) within 12 hours from the onset of symptoms and treated by successful primary PCI.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Pregnant females.\n3. Patients refused to give consent.\n4. Patients who had normal coronary angiography.\n5. Patients who had CTO lesions.\n6. Patients who have SCAD.\n7. Patients who developed dissection or mechanical complication during the procedure.\n8. Patients presenting with cardiogenic shock.\n9. Cardiomyopathies\n10. Contraindications to epinephrine as HTN with SBP \\>180 mmHg or DBP\\>110 mmHg, clinically significant arrhythmia (Atrial fibrillation with rapid ventricular rate, ventricular tachycardia, or ventricular fibrillation) prior to PCI, known allergy to epinephrine.",{"count":166,"type":22},[304],"PHASE3","The aim of this work is to study the role of intracoronary adrenaline administration as a preventive tool for no reflow in patients undergoing primary PCI.\n\nThe main question it aims to answer is:\n\nDo prohylcatic intrcoronary adrenaline reduce the incidence of no reflow without increaing risk of arrhythmia in primary PCI?\n\nThe procedure will be performed by expert operators. All patients will receive the guidelines-directed recommendations of intervention of STEMI patients.\n\nStudy group wil receive Intracoronary 10 mcg adrenaline via the guiding catheter after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and\u002For passage of a deflated balloon and\u002For PTCA with a small balloon, and\u002For use of thrombus aspiration and before stenting.\n\nAll steps in the Cath-lab will be described in detail:\n\nThe primary end points will be improvement in coronary flow, as assessed by TIMI (Thrombolysis in Myocardial Infarction) flow, and myocardial blush.\n\nSecondary end points will be in-hospital mortality and major adverse cardiac events.",[197,307],"No Reflow Phenomenon",[84,309,310,311],"No-reflow","Adrenaline","Prophylaxis","2025-03-07",{"date":314,"type":36},"2025-03-11",{"date":290,"type":36},{"date":317,"type":22},"2026-04-30",{"name":319,"class":43},"Ain Shams University",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":4},"100582289","bivalirudin-with-prolonged-infusion-during-pci-versus-heparin-after-fibrinolytic-therapy-100582289","NCT06861374","Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy","Bivalirudin Plus High-Dose Infusion Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Fibrinolysis: a Randomized Trial","BRIGHT-FIT","Inclusion Criteria:\n\n* Any age\n* STEMI patients received fibrinolysis therapy within 12h of symptom onset and are planned to undergo PCI within 24h of symptom onset.\n* Dual antiplatelet drugs must be administrated according to guidelines before PCI (loading doses and maintenance doses of aspirin and clopidogrel or ticagrelor)\n* Patients requiring staged revascularization of non-culprit vessels within 30 days may be enrolled. In such cases the same antithrombotic agents and PCI procedures must be used in the staged procedure consistent with the index procedure PCI, in particular the assigned antithrombin agent heparin vs. bivalirudin);\n* The subject or legal representative has been informed of the nature of the study, understood the provisions of the protocol, was able to ensure adherence, and signed informed consent.\n\nExclusion Criteria:\n\n* Not suitable for PCI;\n* Mechanical complications (such as ventricular septal rupture, papillary muscle rupture with acute mitral regurgitation, etc.);\n* Cardiogenic shock(Killip IV)\n* Known allergy or contraindications to heparin, bivalirudin, aspirin, or both clopidogrel and ticagrelor\n* Patients who underwent PCI in past 30 days\n* Patients in whom the investigators consider inappropriate to participate in this study (eg, have participated in another drug\u002Finstrument study or undergoing another drug\u002Finstrument study, pregnancy).",{"count":329,"type":22},2400,[25],"This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis. Participants will be randomly assigned in a 1:1 ratio to receive either bivalirudin or heparin, with follow-up at 30 days and 1 year. The primary endpoint is a composite of all-cause mortality and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 30 days.",[28],[334],"STEMI, PCI, fibrinolysis, bivalirudin, heparin, bleeding, mortality","2025-03-03",{"date":337,"type":36},"2025-03-06",{"date":339,"type":22},"2025-05",{"date":341,"type":22},"2029-03",{"name":100,"class":43},{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":352,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":44},"100577169","evaluating-the-safety-and-efficacy-of-drug-coated-autoperfusion-balloons-versus-conventional-drug-coated-balloons-guided-by-ivus-oct-multimodal-imaging-for-treating-acute-myocardial-infarction-opera-ami-study-100577169","NCT06794801","Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study","An Open-Label, Prospective, Single-Center, Randomized Controlled Trial Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study","Inclusion Criteria:\n\n1. Acute ST-Elevation Myocardial Infarction Meeting PPCI Criteria: 1) Chest pain lasting more than 20 minutes, with ST-segment elevation of at least 1 mm in two or more adjacent leads, new left bundle branch block, or evidence of posterior wall myocardial infarction; 2) Onset of symptoms within 12 hours.\n2. Patients Who Have Received Thrombolytic Therapy Within 6 Hours of Symptom Onset and Are Eligible for Rescue PCI Within 24 Hours;\n3. Infarct-Related Artery Selection Imaging and Pre-Treatment Criteria Meeting PPCI Standards: 1) De novo lesions. 2) Reference vessel diameter between 2.5 mm and 4 mm. 3) Successful pre-treatment of target lesions: post-pre-treatment residual stenosis of the culprit vessel ≤ 30%, with no type C dissections (or intravascular imaging indicating significant residual plaque burden at the site of dissection, with transverse expansion \\> 60°, longitudinal expansion \\> 2 mm, dissection involving the media or adventitia, and located at the distal end of the stent), no hematoma, and no significant thrombus (TIMI thrombus burden grade ≤ 2);\n4. Sufficient compliance with the study protocol, agreement to undertake follow-up, and coronary angiography at 9 months;\n5. Voluntary Participation in This Study, Including Signing a Written Informed Consent with Understanding of All Risks and Benefits Described in the Informed Consent Document.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years and \\> 75 years;\n2. History of prior myocardial infarction;\n3. Allergy to contrast agent\u002Finability to tolerate contrast;\n4. Known contraindications \u002F inability to tolerate bivalirudin, fondaparinux, heparin, aspirin, clopidogrel, and\u002For ticagrelor;\n5. Complex coronary lesions: left main lesions, lesions at the ostia of the left anterior descending or circumflex arteries, lesion length \\> 30 mm, severe calcification, severe tortuosity or angulation, bifurcation lesions requiring the implantation of more than two drug-coated balloons (DCBs) or drug-eluting stents;\n6. In-stent restenosis or in-stent thrombus lesions;\n7. Planned simultaneous intervention on non-target lesions;\n8. Active bleeding or recent history of bleeding;\n9. Uncertain neurological outcomes, such as resuscitation;\n10. Intubation \u002F ventilation;\n11. Cardiogenic shock prior to randomization;\n12. Known intracranial disease (tumors, aneurysms, arteriovenous malformations, hemorrhagic CVA, ischemic CVA\u002FTIA within the last 6 months, including permanent neurological deficits from ischemic cerebrovascular disease) ;\n13. Refusal of blood transfusion;\n14. Planned major surgery within 6 weeks;\n15. Stent implantation \\\u003C 1 month prior to enrollment;\n16. Life expectancy of less than 12 months;\n17. Participation in another clinical trial that interferes with this study.",{"count":351,"type":22},134,[25],"Trial Goals:\n\n1. Evaluation of Mid- to Long-Term Safety and Effectiveness of Drug-Coated Autoperfusion Balloon Dilatation Catheter (DCAB) versus Conventional Drug coated balloon (DCB) in Patients with ST Segment Elevation Myocardial Infarction (STEMI).\n2. Evaluation of Hybrid IVUS-OCT System for Intraoperative Evaluation of DCAB or Conventional DCB Treatment Safety and Effectiveness for De Novo Lesions During Emergency Percutaneous Coronary Intervention (PCI) in Patients with STEMI.\n\nThe primary outcome is late lumen loss (LLL) assessed at 9 months following emergency PCI, measured using quantitative coronary angiography (QCA).",[197],[356,357,358,359],"Drug Coated Autoperfusion Balloon Dilatation Catheter","Percutaneous Coronary Intervention","VUS-OCT Multimodal Imaging","De novo lesion","2025-01-22",{"date":362,"type":36},"2025-01-27",{"date":364,"type":22},"2025-01",{"date":366,"type":22},"2030-12",{"name":368,"class":43},"LanZhou University",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":17,"minAge":375,"maxAge":53,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":44},"100545740","the-effect-of-morning-vs-evening-aerobic-exercise-training-on-cardiac-remodeling-and-function-improvement-in-patients-after-st-elevation-myocardial-infarction-100545740","NCT06385834","The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction","Inclusion Criteria:\n\n* Between 18 and 75-years-old;\n* Typical symptoms of acute myocardial infarction within 24 hours, with ST segment elevation of ≥1mm in two consecutive leads on electrocardiogram\n* After receiving complete revascularization treatment\n* Cardiac function grading I to II without any other serious complications\n* Left ventricular ejection fraction \\>30%\n* Compliant with the guidelines of the American College of Cardiology\u002FAmerican Heart Association for participating in cardiac rehabilitation standards\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Patients with unstable angina\n* severe symptomatic congestive heart failure detectable myocardial ischemia\n* valvular disease requiring surgery\n* severe ventricular arrhythmias\n* severe concomitant life-threatening diseases such as cancer, and rheumatoid disease\n* osteoarticular diseases that may affect the exercise process","17 Years",{"count":377,"type":22},201,[25],"The aim of the study was to intervene in the Aerobic exercise time of patients with STEMI and to explore the optimal exercise time for STEMI patients",[28],[382,383,384],"Circadian rhythm","ST-segment Elevation Myocardial Infarction","Aerobic exercise","2024-12-27",{"date":387,"type":36},"2024-12-31",{"date":389,"type":36},"2024-04-30",{"date":391,"type":22},"2028-07-30",{"name":393,"class":43},"RenJi Hospital",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100570241","phase-3-a-randomized-controlled-trial-on-the-efficacy-and-safety-of-butylphthalide-in-reducing-myocardial-infarction-size-and-improving-outcomes-in-stemi-patients-after-primary-pci-100570241","NCT06704685","A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI","A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI - A Prospective, Multicenter, Randomized, Placebo, Double-blinded End Trial.","RISE","Inclusion Criteria:\n\n1. Age range of 18-75 years, encompassing both genders;\n2. Patients presenting with an initial clinical diagnosis of acute ST-segment elevation myocardial infarction (STEMI), within a maximum time frame of 12 hours from the onset of pain to consideration for trial inclusion, who fulfill the criteria for percutaneous coronary intervention (PCI) and express their intention to undergo PCI;\n3. The subject and their legal representative possess the capacity and willingness to provide informed consent by signing.\n\nExclusion Criteria:\n\n1. Uncontrolled hypertension (systolic blood pressure≥200mmHg and\u002For diastolic blood pressure≥110mmHg);\n2. Previous PCI or CABG;\n3. Long-term use of loading doses of anticoagulant or antiplatelet drugs;\n4. History of hemorrhagic stroke or ischemic stroke within 6 months, peptic ulcer, prolonged cardiopulmonary resuscitation (more than 10 minutes) within the last 6 weeks, surgery, or major trauma;\n5. Known allergy to butylphthalide or excipients;\n6. Patients with any of the following conditions: cardiogenic shock, chronic congestive heart failure NYHA class ≥III, severe hypotension, pulmonary insufficiency, severe hepatic and renal insufficiency;\n7. History of congenital or acquired hemorrhagic diseases, coagulation factor deficiency diseases, thrombocytopenic diseases, etc. Or any of the following laboratory tests (INR \\> 2.0, platelet count \\\u003C 100×109\u002FL, Hb \\\u003C 10g\u002Fdl);\n8. Pregnancy, lactation, and planning to become pregnant within 30 days;\n9. Severe mental disorder, alcohol dependence or inability to cooperate with informed consent and follow-up due to dementia;\n10. Concurrent malignant tumor or severe systemic disease with expected survival time less than 30 days;\n11. Have participated in or are currently participating in another clinical intervention study within 30 days before randomization;\n12. Other reasons for not being eligible for the study.",{"count":403,"type":22},40,[304],"This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether \"butylphthalide +PCI\" combined treatment mode on the basis of traditional drug therapy could reduce myocardial infarct size, improve cardiac function and long-term prognosis of patients with acute myocardial infarction, and verify the drug safety of butylphthalide in the treatment of STEMI within the window period of 12 hours.",[28],"2024-11-25",{"date":409,"type":36},"2024-11-26",{"date":411,"type":22},"2024-12-01",{"date":413,"type":22},"2025-12-31",{"name":415,"class":43},"Xiangya Hospital of Central South University",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":428,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":439},"100378818","thrombus-aspiration-in-stemi-patients-with-high-thrombus-burden-100378818","NCT04212494","Thrombus Aspiration in STEMI Patients With High Thrombus Burden","Thrombus Aspiration in Primary Percutaneous Coronary Intervention for STEMI Patients With High Thrombus Burden","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. STEMI patients undergoing primary PCI within 12 hours after the onset of symptoms;\n3. High thrombus burden after guidewire passes the lesion (TIMI thrombus grade ≥3);\n4. Informed consent must be voluntary;\n\nExclusion Criteria:\n\n1. Haemodynamic instability or cardiogenic shock;\n2. After thrombolytic therapy;\n3. The predicted survival time is less than 6 months due to non-cardiac disease;\n4. History of coronary artery bypass grafting;\n5. Participate in other researches within 30 days;\n6. Preoperative gastrointestinal bleeding or contraindications to dual antiplatelet therapy;\n7. Patients were considered unsuitable by other researchers.",{"count":424,"type":22},3838,[25],"This is a prospective, multicenter, open-label, randomized, controlled, parallel group study, in which ST-segment Elevation Myocardial Infarction (STEMI) patients with high thrombus burden(TIMI thrombus grade ≥3) are included. Patients are randomized to be treated with or without manual thrombus aspiration(TA) during primary percutaneous coronary intervention(PPCI) by a ratio of 1:1.",[28],[85,429,430,383],"Coronary Intervention","Thrombus Burden","2024-11-14",{"date":433,"type":36},"2024-11-18",{"date":435,"type":36},"2020-08-30",{"date":152,"type":22},{"name":438,"class":43},"Guangdong Provincial People's Hospital",50,{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":466},"100432546","cardioprotective-effect-of-dexmedetomidine-in-patients-with-st-segment-elevation-myocardial-infarction-100432546","NCT04912518","Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction","Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial","COOPERATION","Inclusion Criteria: the enrolled subjects must meet all of the following criteria:\n\n* Aged 18-75 years old (inclusive);\n* Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2 or more contiguous precordial leads (one of which should be V2, V3, or V4);\n* Sign the informed consent form.\n\nExclusion Criteria: subjects who meet any one of the following criteria are excluded from the study:\n\n* Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;\n* Sinus bradycardia (heart rate sustained \\\u003C60 beats\u002Fmin), PR interval\\> 240ms or II-III degree atrioventricular block;\n* Continuous systolic blood pressure \\\u003C120mmHg;\n* Severe breathing difficulties, aterial blood oxygen saturation \\\u003C92%;\n* Thrombolytic therapy has been performed before the first medical contact in the hospital;\n* Consciousness disorder or past cerebrovascular disease;\n* Previous history of myocardial infarction or PCI\u002FCABG treatment;\n* Known severe liver and kidney dysfunction;\n* Known allergy to dexmedetomidine;\n* CMR contraindications: such as claustrophobia, pacemaker or ICD implantation;\n* Pregnant or lactating women;\n* Malignant tumor or expected survival time \\\u003C1 year;\n* Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, poor compliance, inability of the patient to comply with study procedures and\u002For follow up);\n* Participate in other randomized controlled studies at the same time.",{"count":449,"type":22},250,[25],"This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h of symptom onset and undergo primary percutaneous coronary intervention (pPCI). Patients who meet the inclusion criteria and without exclusion criteria were randomized 1:1 into the dexmedetomidine (DEX) group or the placebo (saline) group after signing the informed consent. In the DEX group, intravenous injection of DEX was started immediately after enrollment, covering the entire PCI operation, and the administration was stopped at the end of the pPCI. The administration of saline was the same as those in the DEX group. The primary endpoint was the myocardial infarct size (MIS) as assessed by cardiac magnetic resonance imaging (CMR) at 5±2 days post-STEMI. Based on a superiority design and assuming an 20.0% relative infarct size reduction (from 26.0% to 20.8% with a SD of 13.0%), 250 patients are required to be enrolled, accounting for 20% drop-out (α= 0.05 and power= 80%).",[28,357,453],"Cardioprotection",[28,455,456,453],"Percutaneous coronary intervention","Dexmedetomidine","2024-10-11",{"date":459,"type":36},"2024-10-15",{"date":461,"type":36},"2021-05-27",{"date":463,"type":22},"2025-12",{"name":465,"class":43},"Harbin Medical University",9,{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":474,"enrollmentInfo":475,"targetDuration":477,"studyType":142,"phases":4,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":44},"100561151","the-prognostic-value-of-anion-gap-in-predicting-major-adverse-cardiovascular-events-among-patients-with-st-segment-elevation-myocardial-infarction-100561151","NCT06586424","The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction","ANGIO-STEMI","Inclusion Criteria:\n\n* Adults with 18 - 70 years old with diagnosis of STEMI who underwent PPCI\n\nExclusion Criteria:\n\n* History of heart failure due to any causes\n* Cardiogenic shock before PPCI\n* Any infection at the time of presentation\n* Pregnant woman\n* Other causes of high anion gap levels such as chronic kidney disease, metabolic acidosis, etc","70 Years",{"count":476,"type":22},80,"7 Days","This study aims to evaluate the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients with ST-segment elevation myocardial infarction. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as ST-segment elevation myocardial infarction and underwent primary percutaneous coronary intervention. The data consist of demographic data, clinical presentation, laboratory, and angiography result were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.",[28],[481,482,483],"anion gap","major adverse cardiovascular events","st-segment elevation myocardial infarction","2024-09-03",{"date":486,"type":36},"2024-09-19",{"date":488,"type":36},"2024-01-01",{"date":490,"type":22},"2024-10-05",{"name":492,"class":43},"Universitas Diponegoro",{"id":494,"slug":495,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":4},"100558214","phase-2-effect-and-safety-of-fexofenadine-hydrochloride-vs-placebo-in-patients-with-acute-myocardial-infaction-a-randomized-clinical-trial-100558214","NCT06548204","Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Ages above 18;\n* Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He\u002Fshe or his\u002Fher legal representative shall provide written informed consent before participating in the clinical trial.\n* Meet the diagnostic criteria for STEMI, the diagnostic criteria includes:\n\n  1. Clinical symptoms: ischemic chest pain lasting for over 30 minites;\n  2. Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit);\n  3. ST segment elevation: new ST segment elevation in two or more adjacent leads on the ECG;\n* Emergency coronary angiography and revascularization should be performed within 12 hours of symptom onset;\n* Ultrasonic cardiogram indicates regional wall motion abnormality, and transthoracic echocardiography shows LVEF ≤ 50% within 72 hours after revascularization.\n\nExclusion Criteria:\n\n* Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors;\n* Previously suffered from myocardial infarction or received coronary artery bypass grafting;\n* History of severe renal failure, estimated glomerular filtration rate (eGFR) \\\u003C 30ml\u002Fmin;\n* History of severe liver dysfunction, total bilirubin (TBil) \\> the upper limit of normal, or AST\u002FALT \\> 3 times the upper limit of normal, or alkaline phosphatase \\> 2.5 times the upper limit of normal;\n* Concurrent severe infections, or liver\u002Fgallbladder obstruction, or history of malignant tumors;\n* Currently receiving immunosuppressive therapy;\n* Pregnant or potentially pregnant and breastfeeding women;\n* Contraindications for fexofenadine hydrochloride or cardiac magnetic resonance examinations;\n* Without obtaining written informed consent.",{"count":500,"type":22},165,[502],"PHASE2","The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.",[28],"2024-08-08",{"date":507,"type":36},"2024-08-12",{"date":509,"type":22},"2024-09",{"date":511,"type":22},"2026-09",{"name":513,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":515,"slug":516,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":522,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":523,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":524,"conditions":525,"keywords":529,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":44},"100442830","metabolic-phenotyping-and-follow-up-of-patients-with-and-without-diabetes-after-new-onset-of-stemi-100442830","NCT05046483","Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI","Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Segment Elevation Myocardial Infarction (STEMI) (DISTEMI Study)","DISTEMI","Inclusion Criteria:\n\n* Condition after new onset of ST-segment elevation myocardial infarction (STEMI)\n* Age 18-80 years\n* HbA1c \\\u003C9.0%\n* People with diagnosis of diabetes mellitus according to ADA and DDG criteria (i.e. HbA1c ≥6.5% and\u002For pathological oral glucose tolerance test)\n* Healthy people with normal glucose tolerance status according to ADA and DDG criteria (i.e. HbA1c \\\u003C5.7% and normal OGTT)\n* People with impaired glucose metabolism (\"prediabetes\") according to ADA and DDG criteria (i.e. impaired fasting glucose and\u002For impaired glucose tolerance and\u002For HbA1c 5.7-6.4%)\n* Consent-able, hemodynamically stable people, without sedation (e.g. opiates) or other interfering medication (e.g. catecholamines)\n\nExclusion Criteria:\n\n* Diabetes mellitus category 3 A-H (ADA criteria), gestational diabetes\n* Current pregnancy\n* Infectious diseases, acute infections \u002F fever\n* Immunosuppressive therapy\n* Severe chronic renal, liver or heart disease (e.g. serum creatinin ≥1.6 mg\u002Fdl, peripheral artery occlusive disease stage IV)\n* Malignant diseases\n* Severe chronic psychiatric illness or addiction\n* Participation in an intervention trial",true,{"count":55,"type":22},"The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI people with diabetes mellitus to people with prediabetes and glucose tolerant people.",[28,526,527,528],"Diabetes Mellitus","Insulin Resistance","Non-Alcoholic Fatty Liver Disease",[530,84,531,532,533,534,535,536,537],"ST-segment elevation myocardial infarction","Cardiovascular diseases","CVD","Diabetes mellitus","Normal glucose tolerance","Non-alcoholic fatty liver disease","NAFLD","Liver fibrosis","2023-08-17",{"date":540,"type":36},"2023-08-22",{"date":542,"type":36},"2018-12-30",{"date":544,"type":22},"2029-12-30",{"name":546,"class":43},"German Diabetes Center",{"id":548,"slug":549,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":568,"leadSponsor":570,"locationsCount":44},"100493782","phase-4-prasugrel-monotherapy-following-primary-percutaneous-coronary-intervention-for-st-elevation-myocardial-infarction-100493782","NCT05709626","PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction","PREMIUM","Inclusion Criteria:\n\n* Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)\n* STEMI patients\n* Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months\n\nExclusion Criteria:\n\n* Patients taking anticoagulants\n* Patients under 18 years old\n* Patients with less than 1 year prognosis\n* Patients participating in other intervention studies",{"count":555,"type":22},2258,[57],"The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).",[28],[560,561,562,357,563],"Acute Coronary Syndrome","Dual AntiPlatelet Therapy","Drug Eluting Stent","ST-elevation myocardial infarction","2023-02-28",{"date":566,"type":36},"2023-03-01",{"date":564,"type":22},{"date":569,"type":22},"2028-01-04",{"name":571,"class":43},"Kindai University"]